Gene therapy is being explored as a means of treating a variety of genetic diseases. Because of the central role of the liver in many metabolic pathways, and the relative ease with which foreign genes can be delivered to hepatocytes, monogenic disorders that result in deficiencies of liver-specific
Prospects for intravascular gene therapy
β Scribed by Roy C. Smith; Kenneth Walsh
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 38 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
The goal of this review is to provide an overview of gene delivery systems and candidate genes currently being evaluated for genetic strategies in vascular gene therapy. We will discuss treatment strategies that have been shown by in vivo model systems to be efficacious in promoting neovascularization of ischemic tissue or limiting postinterventional restenosis by inhibiting smooth muscle cell proliferation and/or encouraging re-endothelialization. J. Clin. Apheresis 12:140-145, 1997.
π SIMILAR VOLUMES
In chronic congestive heart failure, an illness affecting more than 4 million Americans, there is impairment of myocardial extracellular matrix (ECM) remodeling. Failing human ventricular myocardium contains activated matrix metalloproteinases (MMPs), which are involved in adverse ECM remodeling. Ou
Myelomeningocele (MMC) is one of the most common anatomical malformations in humans. Children born with this malformation face a life with crippling disabilities, multiple surgical procedures, and complications. This is made all the more poignant as the majority of these children have normal intelli
It has been approximately 7 years since the introduction of gene therapy. Since conventional procedures such as surgery, chemotherapy, and radiotherapy have had limited therapeutic value for cancer patients, the evolution of gene therapy seems a promising alternative to many researchers and clinicia